高迁移率族蛋白 B1 抑制在自身免疫性疾病中的治疗作用：动物模型的启示。
Inhibition of high-mobility group box 1 as therapeutic option in autoimmune disease: lessons from animal models.
机构信息
Department of Rheumatology and Clinical Immunology, Medical Biology Section, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
出版信息
Curr Opin Rheumatol. 2013 Mar;25(2):254-9. doi: 10.1097/BOR.0b013e32835cee2d.
PURPOSE OF REVIEW
High-mobility group box 1 (HMGB1) is a molecule that has gained much attention in the last couple of years as an important player in innate immune responses and modulating factor in several (auto)immune diseases. Furthermore, advancements have been made in identifying the diverse functions that HMGB1 can play in the body by studying its receptors, pathways and effects. This review will focus on the modulation of HMGB1 in animal models of (auto)immune diseases.
RECENT FINDINGS
In different disease models like sepsis, ischemia-reperfusion and arthritis, HMGB1-blocking therapies have been tested and the disease course was shown to be ameliorated.
SUMMARY
These findings indicate that HMGB1 is an important mediator in innate immunity, inflammation and sterile injury. Furthermore, HMGB1 might be a new therapeutic target in inflammation and autoimmune diseases, which may be translated to the clinic.
综述目的
高迁移率族蛋白 B1（HMGB1）作为先天免疫反应中的重要分子，以及几种（自身）免疫性疾病的调节因子，在过去几年中受到了广泛关注。此外，通过研究其受体、途径和作用，人们在确定 HMGB1 在体内发挥的多种功能方面取得了进展。本综述将重点讨论 HMGB1 在（自身）免疫性疾病动物模型中的调节作用。
最近的发现
在败血症、缺血再灌注和关节炎等不同疾病模型中，已经测试了 HMGB1 阻断疗法，并且表明疾病进程得到了改善。
总结
这些发现表明 HMGB1 是先天免疫、炎症和无菌性损伤的重要介质。此外，HMGB1 可能成为炎症和自身免疫性疾病的新治疗靶点，这可能会转化为临床应用。
Zotero 插件